Table of contents
Table of contents
The Triple Test is a non-invasive prenatal screening method typically performed during the second trimester of pregnancy (between 15 and 20 weeks of gestation). This test analyzes maternal serum to quantitatively measure three biochemical markers:
When combined with clinical information such as maternal age and gestational age, the biochemical results help assess the risk of fetal chromosomal abnormalities including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), as well as neural tube defects.
Free hCGß
This kit is used for the quantitative measurement of the free beta-subunit of human chorionic gonadotropin (free hCGß) in maternal serum.
The DELFIA® Free hCGß assay is a two-site solid-phase time-resolved fluorescence immunoassay using a direct sandwich technique. Two mouse-derived monoclonal antibodies are directed against two distinct epitopes on the free hCGß molecule.
AFP
This kit is used for the quantitative measurement of human alpha-fetoprotein (hAFP) in maternal serum and amniotic fluid.
The DELFIA® hAFP assay is a solid-phase time-resolved fluorescence immunoassay based on a direct sandwich format, in which hAFP is detected using two mouse-derived monoclonal antibodies targeting different epitopes on the hAFP molecule.
uE3
The DELFIA® / AutoDELFIA® uE3 assay is a solid-phase time-resolved fluorescence immunoassay based on a competitive binding principle. Europium-labeled estriol and sample estriol compete for a limited number of binding sites on a rabbit-derived monoclonal antibody specific to uE3.